The use of genetically-derived biomarkers is becoming a fundamental practice in hospitals because of their cost-effectiveness. Since 2005, 95 investors have invested in companies developing biomarkers, raising a total of $1,911M. The average amount invested by each investor is $22M, although there are large differences between investors. Some investors have invested more than $100M, while others have invested less than $150,000.
Investor profile
The characteristics of the investors vary widely. Thus, we find investors dedicated solely to the biotechnology sector such as Biotech Turnaround Fund and DeNovo or multi-sectoral funds such as Jafco Ventureswhich invests in technology-driven start-ups. In addition, there are investors who have only participated in one round of funding related to biomarkers, and investors who have carried out several.
Most active investors by number of rounds in which they have participated.
The most active investors are Mohr Davidow Ventures and Fisk VenturesThe total number of investments made is 5 each.
Mohr Davison, is a firm of venture capital is with more than 30 years of experience, focused on early stage technology companies. This fund has participated in more than 179 companies. In the field of biomarkers, it has allocated $76M with a round of 14M and 2 rounds in On-Q-ity and Tethys BioScience.
Fisk Venturesbetween 2006 and 2013, it has raised 5 rounds of funding in Singulexwhich develops biomarker diagnostic systems that can detect and quantify normal and abnormal protein biomarkers. The total amount invested in the company is $77M.
Investors who have invested the most in the sector
If we take into account the amount invested by inverterthe firm at the top of the list is Viking Global InvestorsThis April 2014, this international firm, with offices in London, Hong Kong, New York and Greenwich, has carried out an financing round of $105M in Adaptive Biotechnologieswhich provides research and diagnostic tools for scientists and clinicians working in the field of genomic immunology.
Second place, with a investment of $99M is occupied by Domain AssociatesThe firm is an American venture capital firm focused solely on the biotechnology sector. This firm has invested in 2 companies related to biomarkers. Astute Medicalwhich develops activities for the identification and validation of protein biomarkers that can serve as a basis for new diagnostic tests, and Sera Prognostics, which develops blood tests to predict problems in pregnancy.
Other posts that may interest you
Caixa Capital Risc launches a new fund in the Biotech sector
Latest investments in "disease diagnostics
EN 
ES